Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence Cook

Showing results (201-210 of 236) with videos related to

Pageof 24
Sort By:
Wellcome Open Research|October 23, 2018
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohortSuceena Alexander, George T John, Anila Korula, et al.
American Journal of Human Genetics|December 25, 2012
Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locusMichael Mueller, Paula Barros, Abigail S Witherden, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2011
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibilityPeter Boross, Victoria L Arandhara, Javier Martin-Ramirez, et al.
Kidney International|February 21, 2018
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indicesIngeborg M Bajema, Suzanne Wilhelmus, Charles E Alpers, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Blood|July 3, 2004
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapySimon N Waddington, Megha S Nivsarkar, Ajay R Mistry, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2005
Membranoproliferative glomerulonephritis type II (dense deposit disease): an updateGerald B Appel, H Terence Cook, Gregory Hageman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 26, 2015
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory ConditionsMichael Thiele, Randolf J Kerschbaumer, Frederick W K Tam, et al.
American Journal of Nephrology|November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 StudiesCarla Nester, Gerald B Appel, Andrew S Bomback, et al.
Pageof 24

Showing results (201-210 of 236) with videos related to

Sort By:
Pageof 24
Wellcome Open Research|October 23, 2018
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohortSuceena Alexander, George T John, Anila Korula, et al.
American Journal of Human Genetics|December 25, 2012
Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locusMichael Mueller, Paula Barros, Abigail S Witherden, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2011
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibilityPeter Boross, Victoria L Arandhara, Javier Martin-Ramirez, et al.
Kidney International|February 21, 2018
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indicesIngeborg M Bajema, Suzanne Wilhelmus, Charles E Alpers, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Blood|July 3, 2004
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapySimon N Waddington, Megha S Nivsarkar, Ajay R Mistry, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2005
Membranoproliferative glomerulonephritis type II (dense deposit disease): an updateGerald B Appel, H Terence Cook, Gregory Hageman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 26, 2015
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory ConditionsMichael Thiele, Randolf J Kerschbaumer, Frederick W K Tam, et al.
American Journal of Nephrology|November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 StudiesCarla Nester, Gerald B Appel, Andrew S Bomback, et al.
Pageof 24